Suppr超能文献

用于左心室辅助装置研究和开发的大动物模型。

Large animal models for left ventricular assist device research and development.

机构信息

From the *Cardiovascular Innovation Institute, University of Louisville, Louisville, Kentucky; †Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, Kentucky; ‡Research Resources Facilities, University of Louisville, Louisville, Kentucky; and §Department of Bioengineering, University of Louisville, Louisville, Kentucky.

出版信息

ASAIO J. 2014 Jan-Feb;60(1):2-8. doi: 10.1097/MAT.0000000000000005.

Abstract

In vivo preclinical testing of left ventricular assist devices (LVADs) warrants a large animal model that faithfully simulates human etiology. Although LVAD recipients are in end-stage heart failure (HF), healthy, young animals have served as the experimental platform for most LVAD research and development (R&D) to demonstrate device safety, reliability, and biocompatibility. The rapidly growing HF epidemic, donor heart shortage, and clinical acceptance of LVAD for bridge-to-transplant therapy (BTT) has led to the expanded role of LVAD for destination therapy and bridge-to-recovery therapy. New paradigms for the clinical care of these emerging patient populations are needed. Clinically relevant, robust, and reproducible large animal models of HF are required to demonstrate efficacy, investigate physiologic responses, elucidate genetic, molecular, and cellular mechanism(s), and develop LVAD control strategies. The animal model must be comparable in size, anatomical structure, and phenotype; the technique used to initiate HF must reflect the clinical portrait, should be technically and financially feasible, result in predictable, stable, and irreversible HF, and demonstrate bidirectionality of the remodeling cascade. In this review, large animal species commonly used in cardiac research, techniques used to create chronic HF, and the combined applicability to preclinical LVAD R&D studies are presented.

摘要

在体临床前测试左心室辅助装置(LVAD)需要一个能够真实模拟人类病因的大型动物模型。尽管 LVAD 接受者处于终末期心力衰竭(HF),但健康的年轻动物一直是大多数 LVAD 研发(R&D)的实验平台,以证明设备的安全性、可靠性和生物相容性。HF 的流行迅速增长,供体心脏短缺,以及临床接受 LVAD 用于桥接移植治疗(BTT),导致 LVAD 在目的地治疗和桥接恢复治疗中的作用扩大。这些新兴患者群体的临床护理需要新的模式。需要具有临床相关性、稳健性和可重复性的大型 HF 动物模型,以证明疗效、研究生理反应、阐明遗传、分子和细胞机制,并开发 LVAD 控制策略。动物模型在大小、解剖结构和表型上必须具有可比性;用于引发 HF 的技术必须反映临床特征,在技术和经济上可行,导致可预测、稳定和不可逆转的 HF,并证明重构级联的双向性。在这篇综述中,介绍了心脏研究中常用的大型动物物种、用于创建慢性 HF 的技术,以及它们在 LVAD 临床前研发研究中的综合适用性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验